RAD
RADIOPHARM FPO [RAD]
Healthcare · ASX Small Cap
$0.0200 +5.3%
Updated 26 Mar 2026 · Scores refresh every scan
⚠ Funding Risk — Cash runway under 4 quarters. Capital raise or funding may be required.
Score Breakdown
Technical38
Catalyst51
Sentiment50
Fundamental76
Momentum52
Risk Gate27
Get alerts when RAD's score changes
Free watchlist with daily scans for 2,200+ ASX stocks
Active Signals
Bullish Signals
- RSI drifting toward oversold territory — worth watching
- Volume surging at 3.3x normal while price falls — heavy selling pressure
- Low cash runway (4 quarters) - dilution risk
- 4C filed 2026-01-27
- Low P/S ratio (2.6x)
- Strong revenue growth (+154%)
- EPS estimates revised upward (+10pts)
- Near 52-week low (4% of range)
- Small-cap ($20-100M)
- CANSLIM I: Institutional ownership (10%)
- Sentiment is mixed — no strong consensus either way
- Revenue growing at +154% — the top line is moving in the right direction
- Altman Z-Score distress zone (0.28 < 1.81, low-confidence approx)
- Penny stock risk ($0.018)
- Beneish M-Score 55.78 > -1.78: likely earnings manipulation
- RBA hiking (-3pts)
Risk Signals
- Trading below both moving averages — the trend is working against this one
- Below the 200-day average — the long-term trend is still working against it
- Deeply negative margins (-286%)
- Not enough chatter to gauge sentiment — defaulting to neutral
- The bigger volume days are the down days — volume-weighted momentum is negative (-0.48%/day)
- Overseas neutral (-2pts, S&P500 neutral, VIX 25)
Ask Scout AI about RAD
3 free messages/day · Unlimited with Pro
Recent Catalysts
NONE RAD101 2nd interim Ph.2b data - 90% achieve primary endpoint
NONE Half Year Report and Appendix 4D 31 December 2025
NONE RAD Doses First Patient in 177Lu-BetaBart (RV-01) Study
LOW RAD to present at NWR Virtual Healthcare Conference
LOW Quarterly Activities/Appendix 4C Cash Flow Report
Recent ASX Announcements
| 2026-03-23 | RAD101 2nd interim Ph.2b data - 90% achieve primary endpoint PRICE SENSITIVE |
| 2026-03-18 | RAD to present at NWR Virtual Healthcare Conference |
| 2026-02-27 | Half Year Report and Appendix 4D 31 December 2025 PRICE SENSITIVE |
| 2026-02-23 | RAD Doses First Patient in 177Lu-BetaBart (RV-01) Study PRICE SENSITIVE |
| 2026-01-27 | Quarterly Activities/Appendix 4C Cash Flow Report PRICE SENSITIVE |
Key Metrics
$42.6M
Market Cap
4.7M
Avg Volume
3.3x
Vol Ratio
$0.02 — $0.04
52-Week Range
0.1%
Short Interest
4 qtrs
Cash Runway
-92.1%
ROE
-286.2%
Profit Margin
CANSLIM Analysis
| Factor | Rating | Detail | |
|---|---|---|---|
| C | Current EPS | fail | EPS Growth: 0% |
| A | Annual Earnings | fail | CAGR: 0% |
| N | New Highs / Catalysts | neutral | |
| S | Supply & Demand | neutral | Float: 100% |
| L | Leader vs Laggard | laggard | RS: -4 |
| I | Institutional Sponsorship | pass | Inst: 10% |
| M | Market Direction | neutral | Neutral |
Sector: Healthcare
Ranked #101 of 117 · Sector avg: 46
View all Healthcare signals →Track RAD and 2,200+ ASX stocks
Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and conviction scoring for every ASX small cap.
No credit card required